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136 PATIENTS WITH MALIGNANT AND NON-MALIGNANT DISEASES: A
REPORT FROM THE AUSTRALIAN AND NEW ZEALAND CHILDREN’S
HAEMATOLOGY AND ONCOLOGY GROUP (ANZCHOG)
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Unrelated cord blood (UCB) is an alternate stem cell source for
patients lacking matched family donors. Speed of availability, tol-
erance of HLA disparity, reduced acute GVHD and reduced risk of
viral disease transmission are advantages of UCB over unrelated
bone marrow. We report the results of all unrelated UCB trans-
plants performed in Australasian paediatric HSCT centres over the
last 10 years. Between April 1995 and July 2005, 136 patients were
transplanted for malignant (n  101; 74%) and non-malignant
(n  33) diseases. Log-rank tests and Cox regression analysis were
used to determine the effects of demographic, graft-related and
treatment factors on engraftment, GVHD, TRM and survival.
Median follow-up for surviving patients is 19 months (range,
1-108). The median age and weight of recipients is 5.1 years
(range, 0.2 to 18) and 19 kg (range, 7 to 101), respectively. Median
infused total nucleated cell (TNC) dose was 4.6  107 NC/kg
(range, 0.7-49.9) and median infused CD34 cell dose was 1.9 
105/kg (range, 0.1-33). 16% of patients received a 6/6 HLA-
matched unit, 44% a 5/6, 39% a 4/6 and 1 patient received a 3/6
HLA-matched unit. The incidence of neutrophil recovery by day
42 was 0.82 (95% [CI], 0.75-0.89) with a median time of 23 days
(range, 10-55) to achieve engraftment (deﬁned as ANC 0.5 
109/L). The incidence of platelet recovery by day 60 was 0.46 (CI,
0.37-0.55) with a median time of 47 days to achieve a platelet
count  20  109/L. Incidences of grades II-IV and III-IV acute
GVHD were 0.41 (CI, 0.32-0.5) and 0.18 (95% CI, 0.10-0.26),
respectively. TRM and survival at 1-year post transplant was 0.31
(CI, 0.23-0.39) and 0.62 (CI, 0.54-0.70), respectively. Leukaemic
relapse at 2 years was 0.23 (CI, 0.12-0.34). In Cox regression
analysis, time to engraftment was consistently the only factor
identiﬁed to be of signiﬁcance. Time to engraftment was signiﬁ-
cantly faster when the infused CD34 dose was 	1.7  105/kg (P 
.001) (median 18 days (CI 16-20) vs. 26 days (CI 22-29). A TNC
dose	3.0 107/kg was associated with higher overall engraftment
rates but had no signiﬁcant impact on speed of engraftment (P 
.08). This large paediatric series conﬁrms that unrelated UCB is a
viable stem cell source and that higher CD34 cell doses results in
a signiﬁcantly faster time to engraftment.
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BONE MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA
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In this study we report the long-term results of bone marrow
transplantation (BMT) in 113 patients (M 56, F 57) with thalasse-
mia major (TM) who were given 117 transplants from HLA iden-
tical sibling donor between May 1983 and September 2005. The
median age was 9.09 years (0.11-28.11). The median number of
transfusions given before BMT was 136 (2-900). The pretransplant
liver biopsy performed in 78 patients showed: chronic persistent
hepatitis in 35, mild chronic active hepatitis (CAH) in 10, moderate
CAH in 23, severe CAH in 10. All patients received the same
preparative therapy consisting of busulphan (BU) (13-14 mg/kg)
and cyclophosphamide (200 mg/kg), preceded by an hypertransfu-
sion regimen for 2-3 weeks. For graft-versus-host disease (GvHD)
prophylaxis, 38 patients were given cyclosporine (CSA) alone and
75 received CSA and short course methotrexate. The median
number of transplanted nucleated cells was 4.8 108/kg (2.3-10.1).
Marrow engraftment was evident in 111 patients. The median time
to achieve 0.5 109/L neutrophils and 50 109/L platelets was 19
(11-37) and 24 (10-55) days respectively. Four patients had an
autologous reconstitution and are currently alive under transfusion
therapy. The probability of graft rejection was 6.6%. The actuarial
probability of developing acute GvHD grade II-IV and cumulative
chronic GvHD was 21% and 17% (7% limited, 10% extensive)
respectively. Transplant related mortality was 8.8%. Ten patients
died for BMT related causes: pneumonia in 4, heart failure in 3,
encephalopathy in 2, aGvHD in 1. Two late deaths occurred, one
for septic shock 54 months post-BMT and one for parotitis carci-
noma 138 months after BMT. As of October 2005, 101 patients are
alive and 97 of them are cured after a median follow-up of 158
months (1-269). The 10-year actuarial probability of survival and
disease-free survival (DFS) was 91% and 87% respectively. In
multivariate analysis, no adverse risk factor affecting survival and
DFS was identiﬁed among recipient-donor age and sex, number of
pre-BMT transfusions, level of ferritin, type of CAH, grade of liver
ﬁbrosis, serum GPT level, HBV and HCV serology, dose of BU,
type of GvHD prophylaxis, marrow cell dose. This study conﬁrms
the feasibility of curing the majority of patients with TM by BMT.
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Leukocyte adhesion deﬁciency (LAD) is an immunodeﬁciency
disease resulting from defects in the integrin CD18. Children
with LAD suffer severe, recurrent bacterial infections due to
failure of leukocytes to adhere to endothelium and migrate to
sites of infection. Approximately 75% of severe LAD patients
die by two years of age. Allogeneic hematopoietic stem cell
transplant after myeloablation can cure LAD, however regimen-
related toxicity and graft-vs.-host disease (GvHD) limit the use
of this approach. Genetic correction of autologous CD34 cells
represents an optimal therapy for LAD since no donor is re-
quired, nor is GvHD a risk. In this study we developed a
retroviral vector that confers a selectable growth advantage for
pre-clinical testing of gene therapy in the canine model of LAD
(CLAD). This retroviral vector allows for correction of the
CD18 defect in CLAD and selection of the corrected cells. The
vector, MSCV(cCD18)IRES-cMGMTP144K, harbors the ca-
nine CD18 cDNA followed by an internal ribosome entry site
(IRES) for expression of mutated canine methylguanine meth-
yltransferase (MGMT). Mutant MGMT confers resistance to
the combination of carmustine (BCNU) and O6-benzylguanine
(BG). A high-titer producer line was identiﬁed using the PG13
packaging line, and supernatant from this producer line was
used to transduce an EBV-transformed B cell line derived from
a CD18- LAD patient. Transduced and mock-transduced cells
were grown in 25 M BG and increasing concentrations of
BCNU. In one experiment, 5 M BCNU  25 M BG allowed
selection of CD18 cells to 	 99% purity, however a distinct
CD18- population remained. In a second experiment, cells se-
lected in 10 M BCNU  25 M BG were  99.9% CD18
with no distinct CD18 population. These studies demonstrate
that a bicistronic retroviral vector leads to selection of a popu-
lation of molecularly corrected LAD cells. Selection was
achieved despite placement of MGMT after the IRES, where
expression of the selectable gene product is expected to be
decreased. Experiments with CD34 cells from CLAD dogs
will allow this approach to be tested in vivo. These studies
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